Cardiome Pharma Corp (NASDAQ:CRME)

CAPS Rating: 1 out of 5

Life sciences company focused on developing proprietary drugs to treat or prevent cardiovascular diseases. Current efforts are focused on the treatment of atrial arrhythmias and congestive heart failure.


Player Avatar genedom (98.11) Submitted: 3/10/2014 3:32:41 AM : Outperform Start Price: $8.68 CRME Score: -5.74

A four-bagger in one year.

Featured Broker Partners